You are viewing the site in preview mode

Skip to main content
Download PDF

Correction: Pilot study investigating the intravenous administration of monomeric L-asparaginase to dogs with multicentric lymphoma 

Veterinary Oncology volume 2, Article number: 6 (2025) Cite this article

The Original Article was published on 14 November 2024

Correction: Vet Oncol 1, 10 (2024)

https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s44356-024-00010-3


Following publication of the original article [1] the following errors were reported for Figs. 4 and 5:

  1. 1.

    Figures 4 and 5 showed an error in the expression of the unite measure.

  2. 2.

    The legends of figures 4 and 5 were switched.

The incorrect and correct versions of Figs. 4 and 5 are given below in this Correction.

Incorrect

Fig. 4
figure 1

Chart showing the plasmatic L-asparagine level, expressed in µmol/L, before and after each day of administration, and on day 21 after the first administration. Monday before the administration (Mon before), Monday after the administration (Mon after), Wednesday before the administration (Wed before), Wednesday after the administration (Wed after), Friday before the administration (Fri before), and Friday after the administration (Fri after). Each dot represents a patient, and the line represents the mean value. Dog 1, 3, 7, 8, 9 received ASNase one week prior ASPAREA®

Full size image
Fig. 5
figure 2

Chart showing the plasmatic L-asparaginase activity level, expressed in IU/mL, before and after each day of administration, and on day 21 after the first administration. Monday before the administration (Mon before), Monday after the administration (Mon after), Wednesday before the administration (Wed before), Wednesday after the administration (Wed after), Friday before the administration (Fri before), and Friday after the administration (Fri after). Each dot represents a patient, and the line represents the mean value. Dog 1, 3, 7, 8, 9 received ASNase one week prior ASPAREA®

Full size image

Correct

Fig. 4
figure 3

Chart showing the plasmatic L-asparagine level, expressed in µmol/l, before and after each day of administration, and on day 21 after the first administration. Monday before the administration (Mon before), Monday after the administration (Mon after), Wednesday before the administration (Wed before), Wednesday after the administration (Wed after), Friday before the administration (Fri before), and Friday after the administration (Fri after). Each dot represents a patient, and the line represents the mean value. Dog 1, 3, 7, 8, 9 received ASNase one week prior ASPAREA®

Full size image
Fig. 5
figure 4

Chart showing the plasmatic L-asparaginase activity level, expressed in IU/mL, before and after each day of administration, and on day 21 after the first administration. Monday before the administration (Mon before), Monday after the administration (Mon after), Wednesday before the administration (Wed before), Wednesday after the administration (Wed after), Friday before the administration (Fri before), and Friday after the administration (Fri after). Each dot represents a patient, and the line represents the mean value. Dog 1, 3, 7, 8, 9 received ASNase one week prior ASPAREA®

Full size image

The original article has been updated.

Reference

  1. Botta V, Camerino M, Bicanová L, et al. Pilot study investigating the intravenous administration of monomeric L-asparaginase to dogs with multicentric lymphoma. Vet Oncol. 2024;1:10. https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s44356-024-00010-3.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. AniCura Animal Oncology and Imaging Center, Rothusstrasse 2A, Hünenberg, 6331, Switzerland

    Vittorio Botta, Mariateresa Camerino, Ludmila Bicanová, Ylva Heidrich & Davide Berlato

  2. Hepius Biotech AG, Hardturmstrasse 103, Zurich, 8005, Switzerland

    Slobodan Tepic & Goran Cvetković

Authors
  1. Vittorio Botta
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Mariateresa Camerino
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Ludmila Bicanová
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Ylva Heidrich
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Slobodan Tepic
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Goran Cvetković
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Davide Berlato
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Davide Berlato.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Botta, V., Camerino, M., Bicanová, L. et al. Correction: Pilot study investigating the intravenous administration of monomeric L-asparaginase to dogs with multicentric lymphoma . Vet. Oncol. 2, 6 (2025). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s44356-025-00018-3

Download citation

  • Published:

  • DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s44356-025-00018-3

Veterinary Oncology

ISSN: 3004-9814

Contact us